Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
Cure Today22h
Neoadjuvant Opdivo Combo Elicits Statistically Significant OS Findings in Resectable NSCLC
Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...
Hosted on MSN20h
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Advanced Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...
PharmiWeb19h
Prostate cancer: HCPs discuss emerging therapies, clinical trials, imaging and AI diagnostics on social media
A new study into the online conversations of healthcare professionals discussing prostate cancer has revealed a strong focus on emerging therapies, the latest clinical trials, AI-driven diagnostics ...